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Abstract
Background: Basal-like breast cancer (BLBC) is a poor prognosis subgroup of triple-negative carcinomas that still
lack specific target therapies and accurate biomarkers for treatment selection. P-cadherin is frequently overexpressed
in these tumors, promoting cell invasion, stem cell activity and tumorigenesis by the activation of Src-Family kinase
(SRC) signaling. Therefore, our aim was to evaluate if the treatment of BLBC cells with dasatinib, the FDA approved SRC
inhibitor, would impact on P-cadherin induced tumor aggressive behavior.
Methods: P-cadherin and SRC expression was evaluated in a series of invasive Breast Cancer and contingency tables
and chi-square tests were performed. Cell-cell adhesion measurements were performed by Atomic Force Microscopy,
where frequency histograms and Gaussian curves were applied. 2D and 3D cell migration and invasion, proteases
secretion and self-renew potential were evaluated in vitro. Student’s t-tests were used to determine statistically
significant differences. The cadherin/catenin complex interactions were evaluated by in situ proximity-ligation
assay, and statistically significant results were determined by using Mann-Whitney test with a Bonferroni
correction. In vivo xenograft mouse models were used to evaluate the impact of dasatinib on tumor growth
and survival. ANOVA test was used to evaluate the differences in tumor size, considering a confidence interval
of 95%. Survival curves were estimated by the Kaplan-Meier’s method, using the log-rank test to assess
significant differences for mice overall survival.
Results: Our data demonstrated that P-cadherin overexpression is significantly associated with SRC activation
in breast cancer cells, which was also validated in a large series of primary tumor samples. SRC activity
suppression with dasatinib significantly prevented the in vitro functional effects of P-cadherin overexpressing
cells, as well as their in vivo tumorigenic and metastatic ability, by increasing mice overall survival.
Mechanistically, SRC inhibition affects P-cadherin downstream signaling, rescues the E-cadherin/p120-catenin
complex to the cell membrane, recovering cell-cell adhesion function.
Conclusions: In conclusion our findings show that targeting P-cadherin/SRC signaling and functional activity
may open novel therapeutic opportunities for highly aggressive and poor prognostic basal-like breast cancer.
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Background
Basal-like breast cancer is an intrinsic molecular subtype
(BLBC) [1, 2] associated with an aggressive biological
behaviour and to a worse patient prognosis, which typic-
ally does not express hormonal receptors and HER2,
constituting the vast majority of triple-negative breast
carcinomas [3, 4]. Until now, targeted therapies are un-
available for these subgroup of breast cancer patients,
mainly due to the absence of well-defined molecular tar-
gets, being chemo and radiotherapy the only therapeutic
options to treat these patients. Consequently, it is urgent
to find specific biomarkers/pathways that could impact
the effective treatment of these poor prognosis breast
carcinomas or accurate predictive molecular indicators
that could be used to select patients for target therapies
already available.
In the last years, our research team has been mainly
focused in identifying key molecules that could be used
as putative molecular targets in BLBC [5, 6]. We and
others have found that the majority of these aggressive
breast carcinomas express the basal marker P-cadherin
(a cell-cell adhesion molecule), which overexpression is
significantly associated to a worse disease-free and
overall patient survival [5, 7, 8], as well as with a
pro-invasive and stem-like cell behaviour [9–14]. More-
over, we demonstrated that P-cadherin inhibition
decreases in vitro cell invasion and sensitizes breast
cancer cells to radiation, as well as decreases in vivo
tumorigenic ability, being indicated as a putative target
for BLBC treatment [14]. We have also shown that
P-cadherin-induced functional effects are due to the
secretion of active proteolytic enzymes, such as MMPs,
and of pro-invasive soluble cleaved-forms of P-cadherin
[9], as well as to the activation of α6β4 integrin [13] and
to the inhibition of the E-cadherin suppressive invasive
function, by the disruption of the E-cadherin/p120ctn
complex at the cell membrane [11]. It is well known that
both cytoplasmic p120ctn and α6β4 integrin activation
can induce the phosphorylation of Src Family Kinases
(SRC) and focal adhesion kinase (FAK), as well as the ac-
tivation of Rac1 small GTPase [15–17]. There are several
lines of evidence showing that tyrosine phosphorylation
of these enzymes may play a role in the disruption of
cell-cell adhesion, due to loss of cadherin/catenin associ-
ation, with a huge impact in cancer progression. Import-
antly, we have described that P-cadherin expression
induces SRC activation in breast cancer cells, suggest-
ing that SRC signaling is being upstream regulated by
this cell-cell adhesion molecule [13, 18]. Thus, in
order to evaluate the role of P-cadherin/SRC signaling
activation in BLBC cells, we have used dasatinib (an
FDA approved SRC inhibitor) to block this pathway
and prevent P-cadherin induced aggressive behavior
of BLBC cells.
Methods
Cell culture and siRNA transfections
Human breast cancer cell (BCC) lines were obtained as
follows: MCF-7/AZ was provided by Prof. Marc Mareel
(Ghent University, Belgium); SUM-149 was kindly pro-
vided by Dr. Stephen Ethier (University of Michigan,
USA); BT20 and MDA-MB-468 were obtained from
American Type Culture Collection (Manassas, VA,
USA). The MCF-7/AZ cell line is a variant of the human
BCC line MCF-7 that expresses basal levels of
P-cadherin. This cell line was retrovirally transduced to
encode only EGFP (LZRS-IRES-EGFP plasmid, MCF-7/
AZ.Mock cell line) or both P-cadherin and EGFP
(LZRS-P-cad-IRES-EGFP plasmid, MCF-7/AZ.P-cad cell
line), as previously described [19]. MCF-7/AZ.Mock cell
line was used as a control.
Cells were routinely maintained at 37 °C, 5% CO2, in
the following media (Invitrogen Ltd., Paisley, UK): 50%
DMEM + 50% HamF12 (MCF-7/AZ, SUM149) and
DMEM (BT20, MDA-MB-468), supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 IU/ml
penicillin and 100 mg/ml streptomycin (Invitrogen, UK).
SUM149 medium was supplemented with 5 μg/ml of
insulin and 1 μg/ml of hydrocortisone (Sigma-Aldrich,
St. Louis, MO, USA).
Transfections of validated small interfering RNA
(siRNA) specific for P-cadherin (Hs_CDH3_6, GW Vali-
dated siRNA, Qiagen, Cambridge, MA, USA) and SRC
(Hs_SRC_1 FlexiTube and Hs_SRC_11 FlexiTube
siRNA, Qiagen) was carried out using Lipofectamine
2000 (Invitrogen), in a final concentration of 50 nM
(CDH3 and SRC1) and 100 nM (SRC11), according to
the manufacturer’s recommended procedures. After
incubation for 5 min, the siRNA and Lipofectamine
2000 solutions were mixed, incubated for 20 min, and
added to cell culture medium. A siRNA control, with no
homology to any gene, was also used (Qiagen), to verify
the specificity of the results obtained.
Drugs and antibodies
Dasatinib was obtained from Sequoia Research Products
(Pangbourne, UK), dissolved in DMSO, and cells were
treated at a final concentration of 100 nM each 24 h for
a total period of 48 h. PP2 (P0042, Sigma-Aldrich) was
dissolved in DMSO and added to the cells at a final
concentration of 1 and 10 μg/ml.
Monoclonal antibodies were obtained as follows:
E-cadherin (WB) (Takara Bio Inc., Shiga, Japan); P-cadherin
(WB) and p120ctn (BD Transduction Laboratories, Palo
Alto, CA, USA); E-cadherin (PLA, IF, IHQ), P-cadherin
(IF), total Src (L4A1) and pSRC(Tyr416) (Cell Signaling
Technology); β-actin (Santa Cruz Biotechnologies, Santa
Cruz, CA, USA). The detailed conditions for each antibody
are described on Additional file 1: Table S1.
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Cell-cell adhesion measurements by atomic force
microscopy
Cells were cultured in a tissue culture dish at a low cell
density concentration to have only dispersed cells, with-
out reaching cell confluence. On the day of the experi-
ment, cells were washed twice with PBS and 1 mL of
serum-free DMEM was added. For the cell-cell adhesion
experiments, tipless arrow TL1 cantilevers (Nanoworld,
Neuchatel, Switzerland) were used, with a nominal
spring constant of 0.03 N/m. Cantilevers were cleaned
for 15 min with UV light and coated with poly-D-lysine
(50 μg/ml) for at least 30 min. Cantilevers were left in
the poly-D-lysine solution until used.
Isolated cell suspensions were obtained after 1 h of
incubation in PBS (without trypsin treatment) of conflu-
ent cells in a separate dish and subsequent pipette
dispersion. The cells and the functionalized cantilevers
were mounted on the CellHesion module (JPK Instru-
ments, Berlin, Germany), with a 100-μm z-range piezo-
electric scanner, connected to the NanoWizard II atomic
force miscroscope mounted on the top of an Axiovert
200 inverted microscope. 100 μL of cells suspension
were injected into the cells substrate dish. Cells were
allowed to settle for 30 s before capturing by a function-
alized cantilever of one cell using the AFM contact
mode. After 30 s of cantilever pressing onto the cell, the
cantilever was raised 100 μm on the z-range and the
attached cell allowed to rest for 1 min before initiating
the contact with an adherent cell on the substrate
underneath. Cell-cell contact was established with an
applied force of 300 pN, in constant height and
closed-loop mode. The AFM tip resonant frequency was
maintained at 2 Hz and a cell-cell contact time of 5 s
was maintained before cantilever retraction, with a
z-range displacement of 50 μm). Five force-distance
curves were performed on each cell on the substrate,
with a 5 s pause between them. A maximum of 8 differ-
ent adherent cells on the substrate were tested with the
same cell attached to the AFM cantilever.
Western blot
Protein lysates were prepared from cultured cells in ca-
tenin lysis buffer [1% (v/v) Triton X-100 and 1% (v/v)
NP-40 (Sigma) in desionized PBS] with 1:7 proteases
inhibitors cocktail (Roche Diagnostics GmbH). Cells
were washed twice in PBS and were allowed to lyse in
500 μl of catenin lysis buffer for 10 min, at 4 °C. Lysates
were then submitted to vortex 3 times, centrifuged
10 min (14,000 rpm) and supernatants were collected.
Protein concentration was determined using a Bradford
assay (BioRad protein quantification system, BioRad,
Hercules, CA, USA). Proteins were dissolved in Sample
Buffer [Laemmli with 5% (v/v) 2-β-mercaptoethanol and
5% (v/v) bromophenol blue] and boiled for 5 min at 95 °
C. Samples were then separated by 8% SDS-PAGE. Pro-
teins were transferred into nitrocellulose membranes
(Amersham Hybond ECL, Amersham biosciences, Buck-
inghamshire, UK) at 130 V for 1 h. For immunostaining,
membranes were blocked with 5% (w/v) non-fat dry milk
in PBS containing 0.5% (v/v) Tween-20. Membranes were
subsequently incubated with primary antibodies for 1 h
at RT (E-cadherin – dilution 1:1000; P-cadherin –
dilution 1:500; p120ctn – dilution 1:1000; tSrc – dilution
1:500; pSRC(Tyr416) – dilution 1:500 and β-actin – dilu-
tion 1:1000), followed by four 5 min washes in PBS/
Tween-20 and incubation with horseradish peroxidase-
conjugated secondary antibodies (donkey anti-goat, goat
anti-mouse, goat anti-rabbit – dilution 1:2000) for 1 h.
Membranes were then washed for 30 min in PBS/
Tween-20. Proteins were detected using ECL reagent
(Amersham biosciences) as a substrate. Blots were ex-
posed to an autoradiographic film. Band quantification of
western blots was performed using Quantity One
(BioRad). Each immunoblot was performed at least three
times, and the ones selected for figures are representative
experiments.
3D breast cancer cells spheroids culture
Aggregoids were obtained by performing the slow aggre-
gation assay, as previously described [19]. Briefly, 1 × 104
cells in 200 μL medium were seeded on solidified agar in
a 96-well plate for 12 h. Medium containing the formed
cellular aggregates (10–100 cells) were centrifuged and
further embedded in acid solubilized rat tail collagen I
gels (1.7 mg/ml collagen I in PBS; 22.5 mM NaHCO3;
8 mM NaOH; 9% of non-supplemented culture
medium). Cellular aggregoids were plated in a 8-well
coverslip bottom chambers (IBIDI, Germany) followed
by 30 min incubation at 37 °C to allow polymerization.
After that time, medium with or without dasatinib was
added to the cellular 3D aggregoid cultures. The in vitro
behaviour was followed by time-lapse microscopy (Leica
microscope - DMI6000B with Adaptative Focus Control)
during 18 h. Further, the images taken were converted
into a time-lapse movie, and quantitative analysis of the
number and length of protrusive structures was per-
formed using Leica AF6000 software.
Immunofluorescence analysis
Cells were cultured on glass coverslips, fixed with 4%
paraformaldehyde (20 min), treated with NH4Cl (50 mM)
for 10 min, washed with PBS, and permeablilized with
0.1% Triton X-100 in PBS for 5 min, at room temperature.
Non-specific binding was blocked by treatment with 5%
BSA in PBS, for 30 min at room temperature. Cells were
then stained Orange-phalloidin (Sigma, St. Louis, MO, USA)
in order to visualize F-actin, for 30 min, or with the mono-
clonal mouse antibody for p120ctn (dilution 1:100) and
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monoclonal rabbit antibody for E-cadherin (dilution
1:100) for 1 h, followed by conjugated goat anti-mouse
and anti-rabbit secondary IgG (Dako Cytomation, Carpin-
teria, CA, USA), for 1 h at room temperature. After an-
other wash with PBS, each sample was mounted with
Vectashield (Vector Laboratories, Inc., Burlingame, CA,
USA) containing 4,6-diamidine-2-phenylindolendihydro-
chrolide (DAPI) and visualized with Leica DM 2000
microscope (Leica).
Matrigel invasion assays
Matrigel invasion assay was performed using 8 μm pore
size BD BioCoat™ Matrigel Invasion Chambers (BD Bio-
sciences), according to manufacturer’s recommenda-
tions. Briefly, 24 h after siRNA transfection, 5 × 104 cells
were added to the upper compartment of the chamber,
with or without dasatinib treatment. In the lower com-
partment, only fresh medium supplemented with 10%
FBS was added. After 24 h (BT20) or 48 h (MCF-7/AZ)
of incubation at 37 °C, the upper surface of the filter was
cleared from non-invasive cells with a cotton swab and
washed with PBS. The invasive cells were fixed with cold
methanol and stained with DAPI. Invasive cells were
scored by counting the cells in the filter with a fluores-
cence microscope (Zeiss Imager Z1), at 100× of magnifi-
cation. Invasion index expresses the ratio between
invasive cells from the different conditions relative to
the control cells.
Wound-healing assay
After transfection, for 24 h, with the respective siRNAs,
cells were tripsinized and seeded for another 24 h, to
allow the cells to form a complete monolayer. After they
became confluent, wounds were carefully introduced
across the cell monolayer, so that the surrounding cells
were not disturbed. The medium was replaced with fresh
complete medium, with and without dasatinib treatment.
Pictures were taken at 100× of magnification in an
inverted microscope (Zeiss), and measurements of the
distance between the wound edges were made at specific
time points.
Zymography
The conditioned medium collected from the several cell
cultures, which were grown 6-well plates coated with
collagen type I, was analysed for proteinases activity
using β-casein zymography. Samples were mixed with
sample buffer [0.03% bromophenol blue, 0.25 M
Tris-HCl pH 6.8, 10% SDS (w/v) and 4% sucrose (w/v)]
and electrophoresed, under non-reducing conditions, on
10% polyacrilamide gels containing 0.1% (w/v) β-casein
from bovine milk (Sigma). After electrophoresis, gels
were washed twice, for 30 min, in 2% (v/v) Triton X-100
(Sigma) at room temperature, in order to remove SDS.
β-casein gels were then incubated in a substrate reaction
buffer [0.2 M NaCl, 5 mM CaCl2, 1% (v/v) Triton X-100
in 50 mM Tris-HCl, pH 7.4], during 72 h, and finally
stained with Coomassie Blue Staining Solution [0.1% (w/
v) Coomassie Blue R250 in 10% (v/v) acetic acid and
40% (v/v) methanol], for 25 min. The gels destaining
was performed in a solution with 20% methanol and
10% acetic acid, until bands start to become visible.
Enzymatic activity was visualized as a clear band against
the blue background of stained casein gels, and MMPs
were identified by their molecular weight. Quantification
of band density was carried out using the Quantity One
software (version 4.0, BioRad, Hercules, CA, USA).
In situ proximity ligation assay (PLA)
Cells were deposited on glass slides and fixed with
methanol for 10 min. PLA was performed using the
Duolink kit (Olink Bioscience, Sweden), according to
manufacturer’s recommendations. The following com-
bination of primary anti-human antibodies were used
against: P-cadherin (dilution 1:50, rabbit polyclonal IgG,
Cell Signaling), E-cadherin (dilution 1:100, mouse mono-
clonal IgG1, clone HECD-1, Takara Bio Inc., Shiga,
Japan; or dilution 1:50, rabbit monoclonal IgG, Cell
Signaling), p120ctn (dilution 1:100, mouse monoclonal
IgG1, clone 98, BD Biosciences). The nuclei were coun-
terstained with DAPI. Slides were analyzed with fluores-
cence microscopy (Zeiss Imager Z1 microscope) for
visualization of bright fluorescent red signals consistent
with protein-protein interaction events. Ten stacks per
image were taken and a minimum of five fields per
experiment were evaluated. The Blobfinder V3.2 free
software (Centre for Image Analysis, Uppsala, Sweden)
was used to quantify the number of blobs (or dots)
present in each condition. For cell culture experiments,
an average of blobs/cells of at least three independent
experiments was performed and was normalized to the
control condition. For paraffin embedded tumors, the
specific number of blobs/cell was analysed. The respect-
ive negative controls were used in each experiment.
Internuclear profile analysis
A software application was developed in order to gener-
ate and analyze the internuclear profile of proteins. In
each immunofluorescent image, pairs of cells were
selected for analysis in a semi-automated manner. The
mapping and quantification of the protein expression
level was performed by computing, respectively, 1D IN
and RD intensity profiles of two contiguous cells and
within one single cell. To cope with cell size and shape
variability, a geometric compensation algorithm was
developed in a Bayesian framework. The method was
designed as an iterative algorithm composed by the fol-
lowing steps: (i) profile extraction from selected single
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cells (in case of RD) or pairs of cells (in case of IN); (ii)
image map building by stacking fluorescence profiles
together in columns after length normalization; (iii)
denoising of map image (in which multiplicative noise
described by a Poisson distribution is assumed); (iv) geo-
metric compensation of each 1D column profile minim-
izing the overall variability of the map along the lines
(horizontal direction); and (v) computation of the
average and standard deviation profiles using the com-
pensated map. After the extraction of the data, the max-
imum mean ratio (MMR) parameter was calculated
dividing the maximum fluorescence value (numerator)
by the fluorescence mean (denominator).
Animal studies
N:NIH(S)II-nu/nu mice, strain produced by Ipatimup,
were housed, breeded and maintained at the CIM-FMUP
Animal House, in a pathogen-free environment under
controlled conditions of light and humidity.The experi-
ments consisted on the orthotopic injection in the mam-
mary fat pad of female mice, with 6–8 weeks of age,
with 2 × 106 cells from each P-cadherin-overexpressing
breast cancer models (SUM149PT, n = 17; BT20, n = 15;
MDA-MB-468, n = 13) using a 25G needle. When the
induced primary tumours reached a median volume of
100 mm3, mice were randomized into two groups, and
started the oral daily treatment with dasatinib, whereas
the others were treated just with the drug vehicle, until
the end of the experiment. Doses of dasatinib to be ad-
ministered were prepared weekly by dilution in citrate
buffer 80 mM (pH = 3.1). The citrate buffer was pre-
pared as follows: sodium citrate powder was diluted in
citric acid solution 1 M, obtained by dissolving citric
acid in deionized water, to a final concentration of
80 nM and with pH = 3.1. The citrate buffer solution
was made every 3 weeks, filtered in flow chamber and
kept at 4 °C. Every week, daily doses of dasatinib were
prepared to a final concentration of 10 mg/kg, in order
to treat mice of both experimental models. Mice (6–8
per group) were weighted, and tumor width and length
were measured with calipers, at least, once a week.
Tumor volume was estimated by using the equation, V
= 0.5 × a × b2, where V is the volume, a is the length of the
major axis of the tumor, and b is the length of its minor
axis. Tumors were surgically removed when an average
volume of 1000 mm3 was reached as previously de-
scribed. Mice were maintained to evaluate the impact of
dasatinib in mice overall survival, for a maximum of
210 days, unless they showed any signs of disease pro-
gression. For that, mice were euthanized accordingly to
the established Endpoints. Upon extraction, Primary tu-
mors were fixed in 10% buffered formalin and then em-
bedded in paraffin, sectioned, and stained with
haematoxylin and eosin. Immunohistochemistry for E-
and P-cadherin was performed in tumors sections.
Immunohistochemistry
A series of 467 primary invasive breast carcinomas
were retrieved from the Pathology Department, Hos-
pital Xeral-Cíes, Vigo, Spain, diagnosed between
1978 and 1992. The tumors have been characterized
for clinical and pathological features as previously
described [11].
IHC was performed as previously described [6]. The
membrane staining extension was evaluated on a scale
of 0 to 3 (0–0% to 10%; 1–10% to 25%; 2–25% to 50%;
3–50% to 100%). For E-cadherin and total Src, scores of
0 and 1 were considered negative and immunoreactivity
of 2 and 3 was scored as positive. For P-cadherin all
tumors presenting an unequivocal membranous staining,
in at least 10% of the neoplastic cells (≥1), were scored
as positive. For pSRC(Tyr416) tumors presenting
membrane or cytoplasmic staining, in at least 10% of the
neoplastic cells (≥1), were scored as positive. Some sam-
ples could not be assessed due to core falling or lack of
enough biological material to analyze.
Statistical analyses
All other statistical analyses were performed by Graph
Pad Prism version 5.0c software (Graph Pad Software,
San Diego, CA, USA), unless otherwise stated. P values
less than 0.05 were considered statistically significant.
For the AFM analysis, Student’s t-tests were used to
determine statistically significant differences. Frequency
histograms were performed in Origin (OriginLab, North-
ampton, MA, USA) and Gaussian curves were applied.
Quantitative parameters of Internuclear profiles (nor-
malized to a constant length of 100 arbitrary units) in
P-cadherin cells were analyzed using a Mann-Whitney
test with a Bonferroni correction.
For the in vivo xenograft assays, ANOVA test was
used to evaluate the differences in tumor size, consider-
ing a confidence interval of 95%. Survival curves were
estimated by the Kaplan-Meier’s method, using the
log-rank test to assess significant differences for mice
overall survival.
Concerning the functional in vitro assays, all were per-
formed independently and in triplicate.
For statistical analysis of the immunohistochemistry
results, contingency tables and chi-square tests were
performed by SPSS 15.0 software package for Win-
dows (SPSS, Inc., USA), to estimate the relationship
between staining patterns of P-cadherin and pSRC
(Tyr416).
All statistical tests were two-sided.
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Fig. 1 (See legend on next page.)
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Results
P-cadherin/CDH3 overexpression is significantly
associated with SRC activation in human breast cancer
cells
In order to confirm the association between P-cadherin
and SRC activation, we started by analysing the expres-
sion of CDH3 (P-cadherin codifying gene) and SRC asso-
ciated genes (SRC, YES1, FYN, LYN, LCK, CSK) in a
public database of breast cancer cell lines belonging to
different molecular subtypes (Fig. 1a) [CCLE database
[20]]. Interestingly, cell lines showing the highest levels
of CDH3 also present a significantly increased expression
of YES, SRC, LYN and FYN. Accordingly, most of these
cell lines were classified as Basal A, which are the ones
that better resemble the BLBC subtype (Fig. 1b-c).
We then validated the association between P-cadherin
and SRC activation using two established in vitro breast
cancer cell models, where P-cadherin expression was
manipulated. P-cadherin overexpressing cells showed
increased levels of pSRC(Tyr416), while P-cadherin
silencing led to a significant decrease of pSRC(Tyr416)
levels (Fig. 1d and Additional file 1: Figure S1A and B).
No alterations in the total levels of SRC were found by
Western blot. E-cadherin and p120ctn were also evalu-
ated in both models and the level of expression and
localization of both proteins were analysed by the fluor-
escence internuclear profiles [21]. In contrast to what
was observed for E-cadherin expression, which did not
alter upon genetic manipulation of P-cadherin, a de-
crease of p120ctn membrane intensity was observed in
P-cadherin overexpressing cells (Fig. 1e-f ). Moreover, a
significant increase in Rac1 activity, a downstream target
of cytoplasmic p120ctn, was observed in cells with
P-cadherin overexpression, as well as the silencing of
P-cadherin in BT20 cells was accompanied by a signifi-
cant decrease in Rac1 activation (Fig. 1g). Cell-cell adhe-
sion strength was also clearly compromised in
P-cadherin overexpressing cells, as demonstrated by
(See figure on previous page.)
Fig. 1 P-cadherin overexpression associates with SRC activation correlating with an aggressive behavior. a Gene expression profile of SRC family
members from BCC lines retrieved from the CCLE database [20]. Unsupervised hierarchical clustering based on classical cadherins expression
(CDH1, CDH2, CDH3), subdivide the BCC lines into their molecular subtype (Luminal, Basal A and Basal B). b Box-plot representation of CDH1,
CDH2 and CDH3 gene expression values in the different breast cancer molecular subtypes. c Box-plot for SRC associated genes expression in the
Luminal and Basal A BCC subtypes. P-values indicate significantly differences observed in gene expression profile from Luminal and Basal A BCC
lines. d Western blot analysis of P-cadherin, E-cadherin, p120ctn, pSRC(Tyr416), total SRC and β-actin proteins after P-cadherin overexpression and
P-cadherin silencing, respectively. e Dual immunofluorescence confocal images using an anti-p120ctn antibody (green), F-actin (red) and DAPI
(blue). f Internuclear profile for p120ctn and E-cadherin, obtained through the computational analysis of immunofluorescence images
from MCF-7/AZ BCC model. P-value indicate significant differences observed in the membrane mean fluorescent intensity for p120ctn
between MCF-7/AZ.Mock versus MCF-7/AZ.Pcad cells. g Quantification of the active Rac1-GTP, measured by a G-Lisa assay after P-cadherin
overexpression and P-cadherin silencing, respectively. h Average values of Work (J), representing the cell-cell adhesion strength, using
AFM Force Spectroscopy analysis. Student’s t-test was used to determine statistically significant differences, and P-values are indicated in the figure.
i Representative Images of time-lapse microscopy for BCC spheroids embedded in collagen type I. Scale bar = 50 μm. j Box-plot quantification of the
extension (μm) of invasive protrusions. k Box-plot quantification of the number of invasive protrusions. l Representation of the percentage of cases
positive for both pSRC(Tyr416) and P-cadherin expression. P-value was calculated by Chi-square test in order to estimate the relationship between
staining patterns of P-cadherin and pSRC(Tyr416)
Table 1 Characterization of the tumor series, conserning tumor
pathological features and molecular markers
N %




ERα Negative 140 33.7
Positive 274 65.9
Missing 2 0.5
HER2 Negative 352 84.6
Positive 60 14.4
Missing 4 1.0
EGFR Negative 395 95.0
Postive 21 5.0
Missing 0 0.0
CKS Negative 357 85.8
Positive 59 14.2
Missing 0 0.0
CK14 Negative 394 94.7
Postive 22 5.3
Missing 0 0.0
Vimentin Negative 345 82.9
Postive 69 16.6
Missing 2 0.5
CD44 Negative 205 49.3
Positive 210 50.5
Missing 1 0.2
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Fig. 2 (See legend on next page.)
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atomic force microscopy (AFM) measurements (Fig. 1h),
as well as a significant increase in the protrusive and
invasive behavior (Fig. 1i-k and Additional file 1: Figure
S1C) of breast cancer cells was promoted, by the evalu-
ation of 3D spheroids embedded in collagen type I
matrix by time-lapse microscopy.
These findings, together with the fact that P-cadherin
affects the E-cadherin/p120ctn complex membrane
stabilization, and that its juxtamembrane domain is cru-
cial for its pro-invasive function [11], led us to presume
that P-cadherin could be modifying cell-cell adhesion
and invasion capacity through p120ctn delocalization
occurring downstream of SRC activation signaling.
Finally, to validate in vivo the association between
pSRC(Tyr416) and P-cadherin, a series of 416 primary
breast tumors was studied by immunohistochemistry
(Table 1). A significant association was found between
the presence of both proteins, where 44% (18 in 41
cases) of the tumors with pSRC(Tyr416) were also posi-
tive for P-cadherin (Fig. 1l).
SRC activity suppression with dasatinib inhibits the in
vitro functional activity induced by P-cadherin
overexpression
Taking into account the results showing a positive asso-
ciation between P-cadherin expression and SRC activa-
tion, we speculated if the downstream SRC signalling
could be an effective target for poor prognostic
P-cadherin-overexpressing breast cancer. This strategy
would overcome the lack of FDA-approved drugs
directly targeting P-cadherin.
Thus, we examined the effect of SRC inhibition in the
previously defined in vitro functional activity induced by
P-cadherin expression, by treating cells with 100 nM of
dasatinib (concentration that does not affect the metabolic
state and viability of breast cancer cells – Additional file 1:
Figure S1D). Breast cancer cells treated with dasatinib
showed a decrease of pSRC(Tyr416) expression (Fig. 2a
and Additional file 1: Figure S1E); moreover, this treat-
ment led to a decrease in cell migration (Fig. 2b) and cell
invasion (Fig. 2c), associated with a decrease of MMP2
activity and sP-cad expression in the conditioned media
(Fig. 2d), as well as with a decreased mammosphere form-
ing efficiency (MFE) (Fig. 2e).
Additionally, cell-cell adhesion was highly promoted in
P-cadherin overexpressing cells treated with dasatinib, as
observed by the brightfield images and quantified by
AFM in both cell lines after SRC inhibition (Fig. 2f ).
Additionally, when we evaluated the in vitro 3D invasion
ability of P-cadherin overexpressing cells after dasatinib
treatment, we observed a significant decrease in the
number and length of protrusive and invasive structures
into the collagen type I matrix (Fig. 2g-i). As a con-
trol, we have performed dasatinib treatment in
P-cadherin low breast cancer cells (MCF-7/AZ.mock
and BT20 siCtr) and, as expected, the impact of the
dasatinib treatment is very modest, since the pathway
is not as activated as in P-cadherin overexpressing
cells (Additional file 1: Figure S2A-C) [22].
Altogether, the results support that SRC activity sup-
pression by dasatinib is able to prevent the functional ef-
fects induced by P-cadherin overexpression in breast
cancer cells.
Dasatinib treatment promotes the recovery of cell-cell
adhesion function by stabilizing E-cadherin/p120ctn
complex at the cell membrane
We have previously shown that P-cadherin overexpres-
sion in an E-cadherin wild-type context weakens cell-cell
adhesion by disrupting the E-cadherin/catenins complex
[11]. Taking this into account, we evaluated the effect of
dasatinib at this molecular level. As observed in Fig. 3a,
dasatinib promoted an increase in membrane expression
of p120ctn, as observed by its internuclear profile
(Fig. 3b), which was associated with a decrease in the
downstream activation of Rac 1 (Fig. 3c). Once again,
E-cadherin expression and localization was not altered
(Fig. 3b), although dasatinib treatment promoted a
significant recover of the E-cadherin/p120ctn complex,
mainly at the cell membrane (Fig. 3d and Additional
file 1: Figure S3A and B). Both results show that acti-
vation of SRC signaling interferes with E-cadherin/
(See figure on previous page.)
Fig. 2 Dasatinib treatment inhibits the in vitro functional activity induced by P-cadherin expression. a Western blotting for pSRC(Tyr416), total Src,
P-cadherin, E-cadherin and p120ctn in P-cadherin overexpressing cells after dasatinib treatment (100 nM) for 48 h. Protein levels of β-actin were
analyzed and used as the loading control. b Representative experiment from a wound healing migration assay, in both P-cadherin overexpressing
BCC (MCF-7/AZ.Pcad and BT20), treated with 100 nM of dasatinib or DMSO for 24 h. c Fold change in the number of invasive cells, evaluated
by the matrigel invasion assay for both MCF-7/AZ.Pcad and BT20 treated with DMSO or 100 nM of dasatinib. d Zymography for MMP2 activity
and Western blotting for sP-cad, using the conditioned medium from cells treated with DMSO or 100 nM of dasatinib for 48 h, in both
MCF-7/AZ.Pcad and BT20 BCC models. e Mammosphere forming assay was performed for both cell models. The P-values indicate the
statistically significant difference between DMSO and dasatinib treated cells, in both P-cadherin BCC models. f Average values of Work
(J), representing the cell-cell adhesion strength, of both BCC cancer cell models treated with DMSO and dasatinib, using AFM Force Spectroscopy
analysis. g Box-plot quantification of the length (μm) and h number of invasive protrusions of MCF-7/AZ.Pcad spheroids, treated with DMSO or
100 nM dasatinib, for 24 h. P-values < 0.05 were considered statistically significant. i Representative Images of time-lapse microscopy for BCC spheroids
embedded in collagen type I, for MCF-7/AZ.Pcad treated with DMSO and dasatinib. Scale bar = 50 μm
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p120ctn complex in agreement with the disruption of
cell-cell adhesion. These results were further validated
using a selective SRC inhibitor (PP2) and by SRC si-
lencing using siRNA (Additional file 1: Figure S4).
We confirmed, by slow aggregation assays, that
dasatinib promoted cell-cell adhesion of P-cadherin
overexpressing cells by rescuing E-cadherin function,
since the treatment with MB2 antibody (that blocks
E-cadherin function) completely abolished cell-cell
adhesion capacity induced by dasatinib (Fig. 3e and
Additional file 1: Figure S2B).
Dasatinib affects in vivo tumorigenic and metastatic
capacity of P-cadherin overexpressing breast cancer cells
In order to evaluate the inhibitory tumorigenic potential
of dasatinib, we used pre-clinical mouse models. We
developed an orthotopic model and protocol to study
the effect of dasatinib treatment in tumour evolution
and recurrence (Additional file 1: Figure S5). Three dis-
tinct P-cadherin overexpressing cell lines were analysed:
SUM-149, BT20 and MDA-MB-468. Dasatinib treated
mice showed an improvement in the wellbeing, as mea-
sured by the % of weight gain (data not shown). Further,
dasatinib treated animals had a significant increase in
overall survival time (Fig. 4a and Additional file 1:
Figure S6A), with a tendency to show a decrease in vas-
cular invasion, as observed in the histology from removed
primary tumors (Fig. 4b). Interestingly, a significant de-
crease in tumour growth (Fig. 4c) was observed with
MDA-MB-468 cells at week 5 post-inoculation, although
the same is not observed for the BT20 and SUM149 BLBC
cell model Molecularly, P-cadherin co-localizes with
pSRC(Tyr416) expression in the tumours recovered from
the mice (Additional file 1: Figure S6B). Importantly, mod-
ifications in the pattern of p120ctn expression and
cell-cell organization were also observed in dasatinib
treated tumours. A significant increase in membrane
p120ctn staining (Fig. 4d-e) could be observed in these tu-
mours, as well as a significant correlation was found
between pSRC(Tyr416) staining and p120ctn cytoplasmic
expression (Fig. 4f). As found in in vitro models, a recov-
ery of the E-cadherin/p120ctn complex interaction to the
cell membrane has also been found in tumours treated
with dasatinib, as measured by PLA (Fig. 4g-i).
CDH3 predicts sensitivity to dasatinib treatment in basal-
like triple negative breast cancer
In view of all in vitro and in vivo data, we hypothesized
that P-cadherin expression could be classified as a pre-
dictive biomarker to stratify BL-TNBC patients for dasa-
tinib treatment.
By the analysis of a previously published gene expres-
sion profile of a data set of BCC lines (GEO accession
number: GSE6569) [23], we observed that CDH3 expres-
sion correlates with the sensitivity/resistance of breast
cancer cells to dasatinib [24]. We have found a statisti-
cally significant association between dasatinib sensitivity
and increased CDH3 expression in Basal A BCC (Fig. 5a).
The same holds for a series of prostate cancer cell lines
(GEO accession number: GSE9633) [25] (Fig. 5b).
Discussion
P-cadherin is overexpressed in more than 50% of
triple-negative breast cancer and is significantly associ-
ated with poor patient survival [7, 26, 27], showing a key
role in some acquired cancer hallmarks, such as in-
creased cell migration, invasion, as well as tumorigenic
and metastatic capacity in breast cancer models [9, 11].
Actually, P-cadherin can be considered as a therapeutic
target in breast cancer, with a particular interest in
BLBC due to the lack of targeted therapies in this spe-
cific subgroup of patients.
Molecularly, P-cadherin in vitro effects are due to in-
hibition of the E-cadherin suppressive invasive function,
by disruption of the E-cadherin/p120catenin complex at
the cell membrane [11]. SRC activation is also described
to have a crucial role in impairing E-cadherin function
and p120ctn delocalization to the cytoplasm [17, 28],
which points for a possible role of SRC activation in
P-cadherin mediated signalling.
Considering all that, our first aim was to show the link
between P-cadherin and SRC activation. Using both gene
expression profiles, in vitro and patient data, we have
demonstrated a clear association between P-cadherin/
CDH3 expression and SRC signature. Actually, previous
publications have already demonstrated, in normal
and in distinct cancer cell models, that P-cadherin
expression activates SRC through its tyrosine phos-
phorylation, being considered one of its main
(See figure on previous page.)
Fig. 3 Dasatinib treatment promotes the recovery of E-cadherin function with stabilization of the E-cad/p120ctn complex to the cell membrane. a Dual
Immunofluorescence for anti-p120ctn antibody (green), F-actin (red), E-cadherin (green) and DAPI (blue) in MCF-7/AZ.Pcad cells after 100 nM
dasatinib treatment for 48 h. Scale bar = 50 μm. b Internuclear profile for p120ctn and E-cadherin, obtained through the computational analysis
of confocal immunofluorescent images. P-values indicate significant differences observed in the membrane mean fluorescent intensity for
p120ctn between MCF-7/AZ.Pcad treated with DMSO versus 100 nM dasatinib, 48 h. c Quantification of the active Rac1-GTP, measured by a
G-Lisa assay, was performed to measure Rac1 activity in P-cadherin overexpressing cells (MCF-7/AZ.Pcad and BT20) treated with DMSO
and dasatinib. d Proximity ligation assay for E-cadherin and p120ctn, for MCF-7/AZ.Pcad treated with DMSO versus 100 nM dasatinib
during 48 h. e 72 h slow aggregation assay images for dasatinib treated MCF-7/AZ.Pcad cells with inhibition of E-cadherin function by MB2
antibody. The images shown are representative ones. P-values are indicated in the figure and considered statistically significant when < 0.05
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signalling pathways to induce invasive and stem cell
behaviour [13, 18, 22, 29].
SRC inhibitors were shown to be the most successful
and promising drugs for TNBC treatment [30, 31]. Specif-
ically, dasatinib (BMS-354825) was identified as a highly
potent inhibitor of SFK, showing anti-proliferative,
anti-migratory and anti-invasive activity in solid tumors
[25]. Nevertheless, clinical trials involving dasatinib for
breast cancer treatment showed limited activity, even in
BL-TNBC subgroup [23, 32, 33]. These negative results
could be most probably due to the lack of previous
selection of the patients that would in fact benefit from
this therapy, as well as due to the high heterogeneity of
TNBC. Therefore, in our opinion, it is imperative to
identify predictive biomarkers linked to SRC signalling
pathway that may constitute a tool for therapeutic
eligibility to dasatinib.
Taking these previous observations into account, and
knowing that the invasive P-cadherin cells have activa-
tion of the SRC pathway [34–37], we tested the func-
tional effect of dasatinib in P-cadherin overexpressing
tumour cells, in order to evaluate the impact of this
adhesion molecule as a therapeutic biomarker in BLBC.
Our results showed that dasatinib inhibits P-cadherin/
SRC signalling significantly preventing the in vitro cellu-
lar effects induced by P-cadherin expression, leading to
a significant decrease in cell migration and invasion,
proteases secretion and mammosphere-forming effi-
ciency. Additionally, dasatinib treatment promoted a re-
covery of an epithelial-like phenotype and induced the
membrane stabilization of the E-cadherin/p120ctn com-
plex, with a significant increase in cell-cell adhesion
capacity. This result was further confirmed by using a
SRC selective inhibitor and a siRNA specific for SRC.
(See figure on previous page.)
Fig. 4 Dasatinib treatment affects the in vivo tumorigenic and metastatic capacity of P-cadherin overexpressing tumors. a Kaplan-Meyer survival
curve for the overall survival of mice treated with DMSO and dasatinib 10 mg/kg, for a maximum period of 210 days. P-value was calculated
using a log-rank test to assess significant differences for mice overall survival. b Percentage of tumours with vascular invasion, observed by HE
staining. Presence or absence of clusters of tumour cells inside blood vessels surrounding the primary tumour was quantified in control versus
dasatinib treated mice (10 mg/kg). c Tumour volume measured at week 5, post inoculation of cancer cells, from control and dasatinib treated
groups, in all BCC models (SUM149, BT20 and MDA-MB-468). d Immunofluorescence for p120ctn (red) and DAPI (blue in the primary tumours
from control and dasatinib treated animals. Scale bar = 50 μm. e Immunohistochemistry for p120ctn and pSRC(Tyr416) in the primary tumours from
control and dasatinib treated animals. The images shown are representative ones. f Quantification of the p120ctn cytoplasmic intensity expression in
primary tumours from control and dasatinib treated animals. g Quantification of the p120ctn membrane intensity. Each dot represents the mean of
p120ctn membrane intensity of 100 pairs of cells from a single biological replicate. Student’s t-tests were used to determine statistically significant
differences, and P-values are indicated in the figure. Scale bar = 50 μm. h Proximity ligation assay for E-cadherin and p120ctn, from tumours recovered
from different mice from control and dasatinib treated groups. i Box-plot for the average number of blobs/cells, quantified using the images of the
proximity ligation assay for E-cadherin and p120ctn, between tumours from control and dasatinib treated mice. Student’s t-tests were used to
determine statistically significant differences, and the P-value are indicated in the figure. Scale bar = 50 μm
Fig. 5 CDH3 expression predicts sensitivity to dasatinib treatment. a Correlation between CDH3 gene expression and IC50 values for dasatinib
treatment in Luminal and Basal A BCC lines. The data was retrieved from a previously published gene expression profile using 23 breast cancer
cell lines to identify genomic signatures highly correlated with in vitro sensitivity to dasatinib (GEO accession number: GSE6569). b CDH3 gene
expression values in dasatinib sensitive and resistant prostate cancer cells. The data was retrived using a dataset of baseline gene expression
profiling of 16 prostatic cancer cell lines used to identify expression signatures highly correlated with in vitro sensitivity to dasatinib (GEO
accession number: GSE9633 [25])
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This data strengthens previous studies, showing that
inhibition of this signaling pathway increases cell-cell ad-
hesion in vivo [38], promoting an epithelial-like morph-
ology and suppressing epithelial tumor cell migration. In
this work, we demonstrated, for the first time, that SRC
inhibition, which is downstream activated by P-cadherin,
recovers the E-cadherin-p120ctn stability and function,
which is crucial for cell-cell adhesion and suppression of
tumorigenesis. Remarkably, P-cadherin overexpressing
cells and tumors treated with dasatinib show a clear
shift of p120ctn expression from the cytoplasm to the
membrane and a recovery of E-cadherin/p120ctn com-
plex interaction at the cell membrane. Phenotypically,
and according to in vitro results, dasatinib treated mice
showed tumors with an epithelial-like phenotype. Both
observations support that dasatinib treatment, by inhib-
ition of SRC, is able to inhibit P-cadherin induced
signaling, promoting a non-invasive epithelial-like
phenotype (Fig. 6). Additionally, CDH3 expression was
able to predict sensitivity/resistance to dasatinib treat-
ment, both in breast cancer and in prostate cancer cell
models. Therapeutically, our observations indicate that
dasatinib is likely to be an interesting option to treat
P-cadherin overexpressing tumours.
Although the effects on tumour growth were not repli-
cated in the different BLBC cell models used, consistent
results were observed in disease progression. Actually,
using mice xenografts, we were able to validate the dasati-
nib effect on decreasing tumour invasion of P-cadherin
overexpressing cells, as well as in the improvement of
mice wellbeing and overall survival of dasatinib treated
mice. This result is in accordance with the in vitro data,
since we do not observe differences in the cell prolif-
eration of dasatinib treated cells, but instead we see a
significant impact on the aggressive biological behav-
ior of P-cadherin overexpressing cells. Similar results
were obtained in an in vivo pancreatic cancer model,
where dasatinib delayed tumor onset and increased
overall survival [35].
Conclusions
In conclusion, our work shows for the first time that
dasatinib counteracts P-cadherin mediated signalling and
functional effects, suggesting this protein as a possible bio-
marker to predict sensitivity/resistance to SRC-directed
therapy. Molecular guiding and selection of patients will
provide the correct tools to treat P-cadherin overexpress-
ing and highly aggressive breast carcinomas.
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BLBC: Basal-like breast cancer; FAK: Focal adhesion kinase; FDA: USA Food and
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Fig. 6 Schematic representation of the proposed model. P-cadherin-overexpressing cells significantly alter their biomechanical properties, presenting
a decreased cellular height, cell stiffness and cell-cell adhesion strength. The activation of a mechanotransduction signaling initiated by P-cadherin
overexpression, promotes an activation of SRC, with a concomitant delocalization of p120ctn to the cytoplasm, disrupting the E-cadherin/p120ctn
complex, and activating the Rac1 small GTPase. Consistently, P-cadherin-overexpressing cells show a significantly higher number of protrusions, as
well as increased protrusion’s length, increased cell migration, invasion, protease activity and self-renew potential. Molecularly, the expression of this
basal marker affects: 1) cell-cell adhesion, through inhibition of the E-cadherin suppressive invasive function; 2) cell-ECM interaction, activating the
heterodimer α6β4 integrin and 3) cell-ECM crosstalk, by regulating the activity of MMP1/MMP2 metalloproteases. Interestingly, inhibiting P-cadherin
downstream SRC activation, using the FDA approved drug dasatinib, lead to a significant decrease in both morphological, biomechanical and
functional properties induced by P-cadherin expression. In conclusion, the results anticipate an important role for P-cadherin in the
mechanotransduction signaling in BCCs, which could be further inhibited by dasatinib
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